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ABSTRACT 
Aim 
The aim was to look at current evidence for treating non-unions or delayed fracture healing in regard to novel 
methods applying mesenchymal stem cells (MSCs) and growth factors (GF). 
  
Methods 
Pre-clinical and clinical trials focusing on the use of Mesenchymal Stem Cells and Growth Factors for fracture 
healing were included in this review. Published articles were identified using specific search terms in Medline, 
Cochrane Library, PubMed, Scopus and Web of Science. 
  
Results 
Of the 580 articles found, 82 met my selection criteria and were included, with 39 papers involving trials on the 
effects of GFs and MSCs on non-unions or bone repair. These included 11 articles on MSCs, 10 on Bone 
Morphogenetic Proteins, 2 on Vascular-Endothelial GF, 5 on Insulin like-GF, 4 on Transforming-GF-β, 4 on 
Platelet-Rich Plasma, 1 on Platelet Derived-GF and 2 on Fibroblast-GF, with the other articles included 
qualitatively. Overall results were positive with the addition of MSCs, Bone Morphogenetic Proteins, VEGF, 
IGF and TGF-β in aiding fracture healing compared to controls, with mixed results for other factors.  
  
Conclusion 
Overall this review shows promising results regarding the use of MSCs and various Growth factors in the 
treatment of fractures and non-unions, as well as synergistic effects observed when combined together. However 
more research is indicated as these methods are still in the early stages of development. 
 
KEY WORDS: Bone Morphogenetic Proteins, Fracture, Growth Factor, Mesenchymal Stem Cells, Non-Union, 
Orthopaedics, Vascular Endothelial Growth Factor. 
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1. Introduction    
Many of the current interventions in the orthopaedic field revolve around repairing or replacing damaged tissues 
with long-lasting, compatible materials with few complications and which are cost-effective. Numerous studies 
have been conducted in the new area of tissue regeneration, and at the forefront of this research is the use of 
stem cells. Stem cells are undifferentiated cells which have the potential to become any specialised cell; they are 
effective and have extensive potential for biomedical research[1]. Mesenchymal stem cells (MSCs) in particular 
are effective as they have the ability to renew and maintain their multipotent nature throughout numerous 
proliferations, with a large number of cells being cultured from only a small sample of bone marrow[2]. MSCs 
have been recognised for years for their potential use in bone grafts and this has led to the identification of a 
number of sources. These include bone marrow, peripheral blood, adipose tissue, teeth and umbilical cord [3,4]. 
These stem cells in particular have the potential to divide into many mesenchymal lineages (such as bone, 
cartilage, muscle)[5,6] when under the right conditions[7], making them invaluable for various processes and 
ideal where immediate applications and increased cellularity may crucially quicken the healing processes[8]. 
MSCs have been studied from the 1960’s and have since been used in tissue engineering to aid in the creation of 
a scaffold; a 3D construct of living tissue seeded with stem cells that will increase tissue repair once 
implanted[2]. They have also been used in various other applications such as direct MSC injection and gene-
modified MSCs, but for bone non-unions and large defects MSC seeded scaffolds have been most successful[9].  
Advancements in biomaterials has allowed the development of scaffolds to enhance regeneration in large 
segmental bone defects and many materials have been researched, including combinations of MSCs, endothelial 
cells and growth factors. These additions have allowed progress and have overcome the drawbacks found 
previously in bone grafting procedures [10]. The currently used grafts include autografts and allografts; 
autografts are considered the ‘gold standard’[11] as they involve cells from the same patient at a different site 
and these grafts include a lattice structure, growth factors and osteoproginator cells. However their 
disadvantages involve donor site morbidity, extended operating times, lack of a vasculature and an increased 
risk of nerve or vessel injury and infections. Allografts were introduced to overcome the downside involving 
donor site morbidity as they can be made in specific quantities from other people’s cells and are called ‘banked 
bone’[12].  However these grafts have increased immunogenic responses, are more expensive and have similar 
drawbacks revolving around lack of blood supply and increased fracture complications and non-unions[13].   
It is important to understand the process of fracture healing in order to properly decide which steps to target or 
which factors to investigate specifically. Fracture healing occurs in four main phases[14] but the basic steps of 
this process include ‘haematoma, inflammation, angiogenesis, chondrogenesis to osteogenesis and bone 
remodelling’[15]. Angiogenesis is essential and occurs in the early stages of fracture healing, when the 
haematoma occurs. This is where inflammatory cells, fibroblasts, stem cells and growth factors are involved.  It 
is important to remember that along with stability of the site, vascularisation is crucial for a successful outcome 
in healing fractures[6]; without which the area of injury would fail to regenerate and die[16]. The sites that are 
most prone to non-unions are those where there is a limited vasculature and therefore an inadequate supply of 
vital proteins, cells and growth factors. These sites include the head of the femur and the wrist bones [6] but also 
the tibial shaft which is a common place of injury and delayed healing.  
The use of growth factors in orthopaedics has also been the subject of important research in this field in the last 
few years. Their use in bone repair is widely known, with many pre-clinical trials but with only limited numbers 
of clinical trials and therefore less available evidence for their current use in helping with orthopaedic 
treatments. The main growth factors which are recognised as key in the process of bone healing and remodelling 
after fracture are bone morphogenetic proteins (BMPs), vascular endothelial growth factor (VEGF), insulin-like 
growth factor (IGFs), transforming growth factor beta (TGF-B), platelet derived growth factor (PDGF) and 
fibroblast growth factors (FGF)[17].  
In this review we will analyse the available literature regarding the application of mesenchymal stem cells and 
various growth factors on bone formation, fracture healing and non-unions.  According to Garrison et al., a non-
union is defined as a fracture that demonstrates motion at the bony end and which has not healed completely by 
6 months[18], but other definitions state it is when there has been no sign of further healing for at least 3 
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months. However, it is difficult to set an exact time limit to classify these fractures [19]. These non-unions have 
been shown to have depleted signalling of essential growth factors in bone healing such as TGF-B and FGF[20] 
and significant reductions in BMP-2 expression was found in the cartilaginous areas of non-healing 
fractures[21].  Non-unions have been reported to occur in a range from 4-10% of fractures and they can lead to 
various morbidities; including severe pain, decreased function and ability to return to work and have a negative 
effect on quality of life[18] as they may require further procedures and longer hospitalisations [13]. Delayed 
union or non-unions can also cause pseudo arthrosis and inability to weight bear or walk because of pain [22]. 
Therefore it is imperative that these fractures are dealt with appropriately and as quick and successfully as 
possible, so it is important to trial various alternative methods such as the use of MSCs and Growth factors as 
they may prove to be a successful direction for future therapeutic applications.  
2. Aims 
The aim of this review was to look at current research and evidence for the use of mesenchymal stem cells and 
various growth factors on the treatment of fractures and non-unions. We wanted to assess if there were any 
benefits or adverse effects in the potential application of these factors in the orthopaedic field.  
3. Methods 
For the purpose of this systematic review we followed the revised PRISMA guidelines (2009) by Moher et 
al.[23].  
3.1 Search strategy  
We searched a range of online databases including OVID/MEDLINE, Cochrane library, Web of science, Scopus 
and PubMed. We used the following search terms ‘Growth factor*’, Mesenchymal stem cell* OR MSC* OR 
stem cell*’, ‘Orthopaedic*’ and ‘Fracture*’ also to narrow down certain searches we searched specific growth 
factors such as ‘BMP* OR bone morphogenetic protein*’, ‘VEGF OR vascular endothelial growth factor*’ or 
‘Fracture OR non-union’.  We also performed hand-searches for articles with similar titles to my review and 
searched relevant article reference lists to try to broaden my search.  
3.2 Selection criteria 
Studies were selected based on the following inclusion criteria: 
1. Study type included preclinical trials, clinical trials and relevant reviews (excluding case series or 
reports) 
2. Studies focusing on the use of mesenchymal stem cells or growth factors in the orthopaedic field 
3. Studies also focusing specifically on their use in fractures or delayed healing/non-unions 
4. No limitations were placed on the type of growth factors used 
5. No limitations on publication year 
6. No limitations on subjects of studies. Included both human (clinical) and animal or cell based (pre-
clinical) trials. 
7. Limitations set on articles having full text available  
3.3 Selection of studies 
To select my studies we performed a search in each of the databases using my keywords, and from here we 
scanned all of the titles that were found. In total there were 626 papers found in my search from the various 
databases and 16 more found by hand searching separately. We subtracted 62 duplicates across the databases 
and made a note of all relevant titles for my review (580). We selected 277 articles from the title screen to read 
their abstracts and assess if they were still relevant, 150 of these abstracts were. We then attempted to access the 
full text of all the papers selected by their abstract and read the full articles. We applied my inclusion criteria to 
each of them, and included all that were relevant and accessible in my review (82), excluding those that did not 
fit the criteria (68). In total we found 39 papers with quantitative data and 43 papers with qualitative data. See 
figure 1 below for my PRISMA flow diagram and a breakdown of the studies found.  
5 
 
 
3.4 Outcomes  
My primary aims were to assess the current evidence on the use of growth factors and mesenchymal stem cells 
in orthopaedics, in relation to treatment and repair of fractures and non-unions. My secondary outcomes were to 
find out which growth factors had been trialled before in both pre-clinical or clinical trials and the mode of 
actions for each of the growth factors and also the various cell sources for mesenchymal stem cells.  
 
3.5 Data collection 
This was extracted independently by one author, and 
information extracted included the types of studies done, 
types of growth factors and stem cells and potential 
adverse effects as well as benefits. We included articles 
with both qualitative and quantitative data.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: PRISMA flow diagram  
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4. Results and discussion  
4.1 Mesenchymal Stem Cells (MSCs) 
It is important to trial allogenic scaffolds with MSCs as an alternative to the gold standard of autologous grafts 
in bone regeneration. Liu et al. studied the efficacy of allogenic mandibular scaffolds and allogenic scaffolds 
loaded with MSCs in beagle dogs[24]. Here the animals received mandibular defects and were divided into two 
groups and assessed routinely throughout the 48 weeks. CT examinations showed that by 48 weeks the allogenic 
MSC loaded scaffolds had been completely replaced by new bone and this surface area was smaller than the 
original indicating resorption of bone had occurred, whereas in the control group the size of the scaffold stayed 
the same as the original meaning little new bone was formed. By 12 weeks the bone mineral density was 
significantly higher than the control group (0.55 to 0.39) and on histological analysis trabecular bone growth 
was only observed in the experimental group.   
Ceramic-based synthetic bone substitutes offer an alternative to allograft and autogenous bone grafts. They are 
based on hydroxyapatite (HA) and tricalcium phosphates and have already been used in clinical practice [12] 
because of their useful bone induction properties[9]. Positive results have been seen regarding MSCs and these 
alternatives, for example Ochi et al. reviewed ‘interconnected porous calcium hydroxyapatite’ (IP-CHA) in 
bone and found along with MSCs it could improve the osteoconductivity and could be used in larger bone 
defects; they subsequently demonstrated successful bone formation in a study of MSC-IP-CHA in rat tibial 
condyles [25].  Wang et al. also looked at similar B-tricalcium phosphate scaffolds combined with MSCs and 
the effect of using a pre-vascularised version in segmental bone defects.  They tested the experimental 
combination against a control of just MSCs in the femurs of rabbits bilaterally. They found that at all times 
analysed in the study the pre-vascularised bone graft had higher volumes of new bone and increased infiltration 
of capillaries compared to the non-vascularised grafts[26]. This could provide an answer to improve vasculature 
in MSC based scaffolds.  
It is well known that MSCs play a role in the induction of bone formation, but Kallai et al. carried out a study to 
identify any further roles carried out by MSCs in bone repair. They genetically engineered MSCs and 
investigated the implantation of these cells on the change in microarchitecture of mouse radial bone fractures. 
They used micro-CT at 10 and 35 weeks to assess the changes compared to limb fracture without MSCs, and 
results showed significant bone remodelling of limbs implanted with MSCs, accounted for by a large decrease in 
bone volume and an increase in mineral density[27] indicating a further role for MSCs other than induction.   
A few studies looked into the addition of molecules other than growth factors on MSCs and the outcome on 
fracture healing. It has been postulated as to why the presence of stem cells is so much higher in an injured site 
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compared with normal tissue. It is thought that MSCs derived from the site of injury recruit other stem cells 
which sense the injury and migrate towards it. Ho et al. hypothesised that certain chemo-attractants played an 
important role in the migration of these MSCs to an injury; they looked at Stromal cell-derived factor-1 and the 
effect of MSC’s expressing it and bone repair.  Rat bone marrow MSCs (rBMC) were harvested and then used 
in 18 3mm femur fractures of other rats. The study had 3 groups; rBMC infected with SDF-1 cells, rBMCs 
alone and the control. In the intervention groups the cells were seeded onto collagen sponges and transplanted 
into the gaps, the control had sponges without cells. The bone mineral content (BMC) was measured at the 1
st
, 
3
rd
 and 6
th
 week and the rBMC-SDF-1 group was found to have a significant increased BMC than the control 
and the rBMC only groups (p=0.003 and 0.0029 respectively). Histology at the site 3 weeks in showed new 
bone formation in all groups, but the largest increase in the SDF-1 group; significantly more than the rBMC 
group of MSCs alone surprisingly and not significantly more than the control. They also carried out a migration 
assay to see whether SDF-1 successfully increases cell migration toward the infected cells. The results showed a 
dose-dependent relationship between SDF-1 and chemo attractive activity as more cells migrated with higher 
doses[7].   
Qi et al. also studied the effect of another factor with MSCs, and here they looked at simvastatin combined with 
MCS sheet transplantation in bone formation. They looked at the response of healing demonstrated by the 
release of BMP-2, alkaline phosphatase, VEGF and callus formation; the group including MSCs with 
simvastatin showed significantly higher expressions of the factors mentioned above and at 8 weeks complete 
bone fusion was obtained. In contrast groups containing two out of the three parts to the experimental group 
showed partial fracture bridging whereas the control still showed non-union. These signify the potentially 
enhanced effects of MSC’s with other factors for non-unions [28]. 
MSCs have been successful in demonstrating osteogenesis actions, but regarding angiogenesis it is thought that 
growth factors are needed in addition to stem cells, particularly VEGF, to produce successful vasculature [16]. 
Kumar et al. demonstrate this as they found successful neoangiogenesis around the bone defect when treating 
non-unions with MSCs expressing BMP-2 and VEGF compared with MSCs alone [29]; these factors were 
found to act synergistically.  To overcome this problem in this type of stem cell Correia et al. looked at the 
potential use of adipose derived stem cells and their individual potential for angiogenesis when stimulated 
appropriately by factors already present in fracture sites. They were attached to scaffolds and subjected to 
various applications of growth factors and different conditions to induce osteogenesis and angiogenesis at 
different times and also simultaneously. They found their data strongly supported the conclusion that adipose 
stem cells could be used as a single source for forming vessels in bone tissue as by week 5 they had evidence of 
vascular network formation by the presence of endothelial cell surface markers and von Willebrand factor [30], 
and thus adipose tissue MSCs could exceed the use of bone marrow MSCs in this respect. Li et al. further 
discussed the positive outcomes to large bone defects in large animals, where adipose derived MSCs modified 
by BMP-2 had a significant effect[31]. 
Furthermore other studies have looked into varying the sources of MSCs or the application of them to enhance 
their effect on bone repair. Although in tissue engineering human bone marrow stem cells are the most 
commonly used site [32,33], alternative sources other than bone marrow MSCs are under investigation[34]; for 
example human umbilical cord MSCs (h-UC-MSCs), which were looked at with blood plasma on bone 
regeneration in rats by Qu et al.. They showed that these cells could successfully heal non-union fractures and 
fracture site density was further enhanced by the addition of blood plasma[35]. Alternatively a study recently 
conducted by Rapp et al. looked into the potential success of systemically delivering bone marrow MSC’s. After 
injecting fluorescent labelled MSCs into mice subjected to femur osteotomies they detected the cells in the early 
and late fracture callus and SDF-1 was strongly expressed at the fracture sites. This factor has been suggested to 
increase cell migration to an injured site. They also induced mechanical ulnar loading to induce bone formation 
in the mice, but they failed to detect any labelled MSCs in these sites; concluding the potential application of 
systemically delivered MSCs to bone injury only. It was not compared to the local application of MSCs though 
so it is difficult to draw appropriate conclusions and it is still debated whether this technique actually aids 
fracture repair once MSCs are recruited [36]. It’s important to note that all of the studies we assessed for MSCs 
were pre-clinical, and current research doesn’t seem to have reached the clinical phase of trials on humans. 
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See table 1 below for a summary of trials involving MSCs.  
Type  Study  Design Cell source Application  Summary  
Pre-
Clinical  
 
Liu et 
al. 
(2014)
[24] 
In vivo Canine 
bone 
marrow 
stem cells 
Canine 
mandibular 
defects 
At 48 weeks the allogenic mandibular scaffolds of the 
experimental group with autologous MSCs had been 
completely replaced by new bone and decreased in size, 
but the control group remained the same size throughout. 
At 12 weeks the bone mineral density in the MSC group 
was significantly higher than the control (P<0.05). 
 
Ochi et 
al. 
(2014)
[25] 
Ex 
vivo 
and In 
vivo  
Adult 
peripheral 
blood and 
bone 
marrow 
Rabbit 
ulnar 
defects 
Results suggested a potential clinical use of magnetically 
labelled MSC for treatments in delayed unions, non-unions 
and bone defects, as this method of delivery promoted cell 
accumulation and proliferation at the fracture site. Study 
was not solely focused on bone applications as they also 
looked at cartilage, ligaments, muscles and nerves. 
Wang 
et al. 
(2010)
[26] 
 
In vivo Bone 
marrow of 
rabbits 
Rabbit 
femur 
osteotomy 
The experimental group had prevascularised bone grafts 
seeded with MSCs and inserted with a vascular bundle 
into the osteotomy. This had a significantly higher volume 
of regenerated bone and capillary infiltration compared 
with the control, which was MSC scaffold alone and non-
vascularised. VEGF was also expressed at a higher level in 
this group than the control group throughout the study.   
Kallai 
et al. 
(2010)
[27] 
 
In vivo  MSCs from 
mice and 
genetically 
engineered 
Radius of 
mice 
Results show that regenerated bone tissue remodels over 
time, with decreased total volume but increased mineral 
density. The axial stiffness of limbs with a non-union 
repaired with MSCs was 2 to 1.5 times higher compared to 
the contralateral intact limbs, at 10 and 35 weeks after 
treatment, with overall superior biomechanical properties.  
Ho et 
al. 
(2014) 
[7] 
In vivo 
and in 
vitro  
Rat bone 
marrow 
MSCs 
Rat bone 
defects 
In vitro they showed that SDF-1 secreted by the 
transfected stem cells increased the migration of 
nontransfected cells. In the rat defect bone model bone 
marrow MSCs overexpressing SDF-1 had significantly 
more new bone formation in the gap and less bone mineral 
loss. SDF-1 was concluded to have in important role in 
fracture repair.  
Qi et 
al. 
(2013)  
[28] 
In vivo 
and in 
vitro  
Rat bone 
marrow 
MSCs  
Rat tibia 
osteotomy   
Tibias were harvested at 2 and 8 weeks, and showed 
increased expression of BMP-2, Alkaline phosphatase, 
osteocalcin, osteoprotegerin and VEGF in simvastatin-
induced MSCs and this further increased with higher 
concentrations of simvastatin, significantly higher than the 
group with MSCs alone. Results show that both 
contributed to the complete healing of the tibia.  
Kumar 
et al. 
(2010)
[29] 
In vivo 
and in 
vitro  
Mice bone 
marrow 
MSCs 
Mouse tibia 
bone 
defects 
Increased bone formation in group with BMP-2 and VEGF 
expressing MSCs. Increased vascularity and 
osteoblastogenesis compared to control.  
Correi
a et al. 
(2014)
[30] 
 
In 
vitro  
Human 
adipose 
derived 
stem cells 
(hASC) 
Applied to 
scaffolds 
hASC were inserted with fibrin hydrogel and a porous 
sponge to form a scaffold, and subjected to various 
applications of growth factors. By 5 weeks of culture bone 
development was evidenced by certain markers such as 
calcium deposition and bone matrix proteins along with 
vascular networks evidenced by endothelial cell surface 
markers. Both support the use of adipose stem cells as a 
source of vascularised bone tissue. 
Li et 
al. 
(2007)
[31] 
 
In vivo 
and in 
vitro 
Adipose 
cells from 
canine 
bone 
marrow 
Canine 
ulnar 
defects 
Adipose cells were genetically modified by BMP-2 and 
applied to B-tricalcium phosophate carrier and implanted 
into bone defects. At 16 weeks analysis showed the 
modified adipose cells produced significant amounts of 
newly formed bone and healed most of the bone defects.  
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Qu et 
al. 
(2012) 
[35] 
In vivo  Human 
umbilical 
cord MSCs 
Rat tibia 
non-union 
Benefits seen in the group treated with these MSCs and 
blood plasma, with higher fracture site density and a low 
immunogenicity which merged with rat bone tissue and 
completed the healing of non-unions. However results 
were not significant and were similar to a control.  
Rapp 
et al. 
(2015)
[36] 
In vivo Mice bone 
marrow 
MSCs 
Mice femur 
osteotomy 
or non-
invasive 
mechanical 
loading of 
ulnar 
Fluorescently labelled MSCs were injected systemically 
into the mice. These were detected in early and late 
fracture callus (day 10 and 21) in the femur osteotomies, 
with a strongly expressed SDF-1which mediates cells to 
the injury site. There was more bone in the callus of these 
mice compared to control however the bending stiffness 
was not altered. They failed to detect the labelled MSCs in 
the ulnar sites where mechanical loading had occurred 
with no bone defect, concluding that these cells are only 
recruited in injury-induced and not mechanically induced 
bone formation.  
Summary and characteristics of trials involving Mesenchymal Stem cells: Table 1 
4.2 Bone Morphogenetic Proteins (BMPs) 
BMP’s are the main group of growth factors that act on the skeleton, as their key actions involve migration of 
osteoprogenitors and osteoinduction and proliferation [17]. They have been extensively researched for these 
properties and have been studied in the context of new bone formation and as an alternative to the current ‘gold 
standard’ of autografts for non-union in fractures and bone defects [37,38]. Only recombinant BMP-2 and BMP-
7 have made it past clinical trials and into practice[17,39]. BMPs have also been studied in a number of 
preclinical studies when they were first introduced as a potential aid to promote bone formation, and the benefits 
of BMP-2  in terms of increased torsional toughness and total callus new bone formation were demonstrated on 
tibial fracture healing in goats[40]. BMP1-3 effects in rabbit and rat models were discussed by Grgurevic et al. 
who found that BMP1-3 (which is found in surrounding plasma and an isoform of the BMP-1 gene) was 
significantly increased in acute bone fracture and found in the surrounding plasma and therefore hypothesised 
that BMP1-3 played a crucial part and also demonstrated that when an antibody was used to neutralise their 
effects there was delayed bone union[41]. A recent study on the therapeutic potential of BMP-9 on MSCs has 
also demonstrated significant cross-talk with other signalling pathways inducing trabecular bone and increasing 
osteogenic markers so potentially could be considered for future clinical use, however more trials are needed 
with BMP-9 before assessing it’s clinical applications [42]. 
BMP-2 has been seen to be advantageous for bone regeneration of acceleration of fracture healing and a number 
of studies have assessed the benefit in a clinical setting. Govender et al. carried out a large prospective 
randomised study on 450 patients to evaluate the effectiveness of addition of recombinant human BMP-2 
(rhBMP-2) on healing of open tibial shaft fractures[43]. Patients were randomised to receive either the standard 
of care for this injury (which is intramedullary nail fixation) or the experimental groups which were standard of 
care with an implant containing either 0.75mg/mL dose of rhBMP-2 or 1.5mg/mL dose contained in an 
absorbable sponge. In their results they found that at the end of the 12 month follow up the group with the 
higher dose of rhBMP-2 had a reduction in risk of failure of 44% and this was found to be significant 
(p=0.0005). A reduction of failure was measured by the need for secondary intervention because of fracture 
non-union; such secondary interventions are associated with higher patient morbidity and reduction in quality of 
life. The rhBMP-2 group with 1.5mg dose had 26% of the patients needing secondary interventions while the 
lower dose rhBMP-2 (0.75mg) and control group had higher proportions of patients requiring this (37% and 
46% respectively). The higher rhBMP-2 group had fewer interventions and complications such as pain, and 
were also shown to have evidence of faster healing, which was assessed by independent surgical and 
radiological opinions.  The higher dose group had evidence of healing starting at 10 weeks and increasing so 
that at 6 months there was a 21% increase in healing rate compared to the control group. However infection 
rates were no different between the groups and surprisingly whilst fracture healing was observed in 50% of the 
patients at the shortest amount of time in the 1.5mg group at 145 days, the lower dose of rhBMP-7 at 0.75mg 
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had a prolonged average time compared to the control (187 compared to 184 days respectively) indicating no 
added benefit at the lower dose. Overall the differences in the results found were significant in terms of the 
higher dose of rhBMP-2 and the effects were concentration-dependant [43].  These results were also reiterated 
by Swiontkowski et al. in 2006 in a subgroup analysis[44], and by Wei et al. in a meta-analysis of rhBMP-2 in 
open tibial fractures[45].  A health economic analysis of the use of BMP-2 in severe open tibial fractures (grade 
III) found that in all three countries analysed (UK, Germany and France) savings were made in terms of more 
secondary interventions due to delayed fracture healing or infection if rhBMP-2 was not used [46]. Overall, it 
would seem the use of rhBMP-2 is beneficial in many aspects. 
BMP-7 is also known as osteogenic protein-1 (OP-1) have been studied by many, including Friedlander et al. 
[47] and Ristiniemi et al. who investigated the effects of rhBMP-7 on accelerating fracture healing [48]. OP-1 
was first implanted successfully on a patient in tibial non-union over 20 years ago and since then has been 
trialled extensively. OP-1 has been found to be safe without adverse effects and successful as an alternative to 
the normal standard of autogenous bone harvested from the iliac crest with improved functional outcomes, such 
as being able to weight-bear without pain earlier on than control groups [49].  BMP-7 has many clinical uses, 
mainly studied in terms of non-unions and fracture healing, but it has also been used in other procedures 
including acetabular reconstruction and enhancement, distraction osteogenesis, free fibular graft and arthrodesis 
of joints. In a large observational study looking into its applications the overall success rate after application of 
BMP-7 in persistent atrophic non unions and other procedures was 82%[50]. 
Ristiniemi et al. conducted a trial of 20 patients with distal tibial fractures treated by external fixation and 
osteoinduction with rhBMP-7, compared with 20 matched control patients. They found significantly more 
fractures had healed by 16 and 20 weeks in the experimental group than the control. The mean time to union in 
weeks was 15.7 in the BMP group versus 23.5 in the control group, and this difference was significant with a p 
value of 0.002. The study also showed a smaller secondary intervention number (2:7) although it was a small 
sample size which could impact upon statistical power of the trial[48]. Bilic et al. also looked at OP-1 (BMP-7) 
but in the healing of scaphoid non-unions with proximal pole sclerosis and randomly assigned a small sample of 
patients (17) to 3 different treatment groups: autologous iliac graft, the same with OP-1 and allogenic iliac graft 
with OP-1. Clinical and radiographic assessments were performed and overall the addition of OP-1 to the first 
group reduced the radiographic healing time by 5 weeks (4 weeks compared to 9) [51].   
In contrast to these results Friedlaender et al. conducted a randomised control study included 124 tibial non-
unions and treatment of intramedullary rod with rhOP-1 or with bone autograft. They assessed the severity of 
pain at site, ability to weight-bear and walk, and the need for surgical re-intervention. Results showed that both 
groups were successful and comparable but whilst 75% of the OP-1 group demonstrated radiological evidence 
of bone bridging at 9 months, the control group had more success at 84%. However surgical re-treatment 
occurred in a lower percentage of OP-1 group compared to the control (5% to 10%) [47].  
Vukicevic et al. recently undertook a review on the use of these two BMPs and in the context of a new carrier 
device OSTEOGROW for aiding in the clinical use of BMPs in bone healing[52] as it has been found that 
BMP-2 and BMP-7 when unbound can cause bone formation in surrounding tissues and inflammation in the 
bovine collagen carriers. But when BMP-6 was attached to this whole blood compatible device it was found to 
accelerate healing of critical size defects in animals without the adverse effects. It’s success has been discussed 
in other reviews[53]. 
Regarding the use of MSCs with BMPs together in the treatment of non-unions the ‘diamond concept’ was 
introduced in recent years, which incorporates the concurrent use of MSCs with Growth Factors and hormones, 
scaffold and mechanical stability [54]. The concept has been shown to be successful when applied to treating 
critical-size bone defects [55] and further studies by Scaglione et al. and Giannoudis et al. on this method on 
long bone non-unions both found that the method was valid [54]. It was also found that in subtrochanteric 
atrophic nonunions which were complicated it allowed optimisation of the environment needed to support 
healing[56]. Similarly Calori et al. analysed the diamond method on 52 patients with forearm non-unions 
randomised to either ‘polytherapy’ using all of the components of the concept versus ‘monotherapy’ with only 
one. Results showed a higher percentage of non-unions that developed radiographic and clinical healing in the 
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polytherapy versus monotherapy group (89%: 64%). The average time to clinical union was also prolonged in 
the monotherapy group (on average 5.29 months compared to 3.65)[57]. However it is unclear how many in the 
monotherapy group was assigned to either MSCs, rh-BMP-7 or a scaffold.   
See table 2 below for a summary of trials involving BMPs.  
Type  Study  Design  Application  Summary  
Pre-Clinical  
 
Welch et 
al. (1998) 
[40] 
In vivo Goat Tibial 
Fractures 
RhBMP-2/ACS group had increased 
radiographic healing scores, increased torsional 
strength and stiffness. Total callus new bone 
volume was significantly increased. 
 
Grgurevic 
et al. 
(2011)  
[41] 
 
In vivo and  
In vitro 
Rodent Long 
Bone (systemic) 
and Rabbit 
Ulna (local) 
BMP1-3 enhanced bone healing in critical 
sized defects. BMP1-3 increased the expression 
of collagen and osteocalcin and enhanced 
mineralisation in vitro in osteoblast cells.   
 
 
Clinical  Govender 
et al. 
(2002) 
[43] 
In vivo  Human open 
Tibial fractures 
 
rhBMP-2 (1.50mg) group had 44% reduction in 
healing failures, significantly fewer 
interventions and faster fracture healing than 
controls. 
A significant difference was not found with the 
lower concentration of rhBMP-2 (0.75mg) 
compared to controls.  
 
Swiontkow
ski et al. 
(2006)  
[44] 
In vivo Human open 
Tibial fractures 
 
Subgroup 1) of severe (type III) open fractures 
had significant improvements in the rhBMP-2 
group, fewer bone-grafting procedures, fewer 
secondary interventions and lower rates of 
infection. No difference in subgroup of reamed 
intramedullary nailing 
 
Friedlander 
et al. 
(2001) 
[47] 
In vivo Human tibial 
non-unions  
 
9 months, 81% BMP-7 group and 85% control 
(autogenous bone) were treated successfully.  
Radiographically control was higher % healed 
 
Ristiniemi 
et al. 
(2007) 
[48] 
In vivo  Human tibial 
fracture 
 
RhBMP-7 group had significantly increased 
fractures healed by 16 and 20 weeks. Time to 
union was decreased in this group. Delayed 
healing and secondary intervention occurred in 
2 patients of the BMP group and 7 in the 
control.  
 
Bilic et al. 
(2006) 
[51] 
In vivo  Human 
Scaphoid non-
union 
 
 
BMP-7(OP-1) improved autologous and 
allogenic bone implants in the non-unions and 
reduced radiographic healing time from 9 
weeks to 4. Increased vascularisation with the 
addition of BMP-7 was observed compared to 
the control (autologous graft without addition 
of BMP-7) 
 
Scaglione 
et al. 
(2014) 
[54] 
 
In vivo  Human long 
bone non-
unions 
Tested the ‘diamond concept’ of MSCs and 
BMPs on non-unions and found complete 
ealing in 78.9% (15 cases) with an average 
healing time of 6.5 months. However there 
were no controls to compare the outcome. 
 
Giannoudis In vivo Human non- 82% success rate with BMPs in treatment of 
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et al. 
(2013) 
[56] 
unions 
 
 
fracture non-union. No local or systemic effects 
were encountered and both clinical and 
radiographical union was seen.  
 
Calori et al. 
(2013) 
[57] 
In vivo Human non-
unions 
RhBMP-7 vs PRP: clinical and radiological 
union in 87% of rhBMP-7 compared to 68% in 
PRP, and a lower clinical and radiographical 
healing time for the BMP-7 group (3.5 vs 4 
months, and 8 vs 9 months) 
Summary and characteristics for trials involving Bone Morphogenetic Proteins: Table 2 
4.3 Vascular Endothelial Growth Factor (VEGF) 
The main biologic effect of VEGF on bone is angiogenesis, but it has also been shown to encourage the 
proliferation and differentiation of osteoblasts[14,17]. It is because of these added properties that VEGF has 
been trialled in tissue engineering research along with other molecular factors and assessed on its ability to 
vascularise and regenerate bone[10]. VEGF is involved in many steps of healing in a fracture, including the 
haematoma, bone turnover and remodelling[58].Whilst it has been tested individually it seems that VEGF 
functions most effectively when used at the same time as other growth factors; in particular bone morphogenetic 
proteins (BMPs)[10]. Aryal et al. recently reviewed the effect of BMP-2 and VEGF in bone tissue regeneration 
in fractures and it seems that although the use of BMP-2 alone has been successful it has drawbacks as it lacks 
the accelerated blood supply aided by the addition of VEGF[37]. The effects of VEGF and BMPs have been 
shown to influence each other simultaneously demonstrated when BMP antagonists were used in assessing MSC 
differentiation in vivo there was a significant decrease in VEGF production by osteoblasts, and vice versa when 
VEGF antibodies were used a subsequent blockade of BMP- angiogenesis occurred , indicating their 
corresponding roles[58]. Kumar et al. also demonstrated this synergistic effect in bone repair when MSCs 
expressing both VEGF and BMP-2 were assessed and the new bone formed for the dual-therapy group revealed 
significant increased peak load, toughness and stiffness of the tibial bone post fracture[29].  However the effects 
of dose were analysed thoroughly and they found that with higher concentrations of VEGF at a local level it has 
been shown to create non-functional and malformed vessels, as well as interfering with stem cell lineage when 
combined with MSC’s at a higher dose. This results in more stem cells tending toward an endothelial lineage 
and reducing the amount with osteogenic effects [37]. 
In order to achieve functional repair of skeletal defects Gao et al. studied the use of MSCs in a collagen scaffold 
with a bolus dose of VEGF, and tested this on bone defects created in the femoral diaphysis of mice[59]. The 
MSC-loaded scaffold were rapidly integrated and mineralised into host bone; this was not seen in empty 
scaffolds and to a lesser extent in MSC scaffolds without the VEGF bolus. The results of these were further 
reiterated in the 2015 trial regarding the effect of VEGF-A165 on the integration of allografts in tibial defects in 
rabbits[60]. However, this study was done to assess the application in regard to defects other than fracture, such 
as those caused by infection or tumour.  See below for a summary of the trials discussed here.  
Type  Study  Trial design Application  Summary  
Preclinical  Kumar et al. 
(2010)[29] 
In vivo and 
in vitro 
Mouse tibia 
bone defects 
Increased bone formation in group 
with BMP-2 and VEGF expressing 
MSCs. Increased vascularity and 
osteoblastogenesis compared to 
control. However increasing 
concentrations created damaged 
and non-functional vessels.  
Gao et al. (2013) 
[59] 
 
In vivo Rodent femur MSC-loaded scaffolds with VEGF 
had increased integration and 
mineralisation into host bone 
compared to control and MSC only 
scaffolds. 
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Ruiz-Iban et al. 
(2015) 
[60] 
In vivo  Rabbit tibial 
defects and 
non-union  
VEGF addition increased trabecular 
content and continuity, decreased 
failures in osteosynthesis and 
integration of the graft 
No difference found in torsional 
strength. 
Summary and characteristics for trials involving Vascular Endothelial Growth Factor: Table 3 
4.4 Insulin like Growth Factor (IGF) 
IGF’s play an important role in the regulation of hormone effects, helping in osteoblast proliferation, bone 
resorption and also in matrix synthesis having an anabolic effect overall[17,22,61]. The group contains two 
proteins IGF-1 and IGF-II but the former is many times more potent and has frequently been found in fracture 
callus and in the expression of osteoblasts and chondrocytes during new bone formation[22]. IGF-1 levels were 
found to decrease initially in fracture repair but double in number 7 days post-operatively[61]. Recent trials have 
looked into the potential enhancement of fracture healing from the addition of IGF to standard treatments but 
also at the synergistic effect when added together with BMPs or MSCs. A study by Koh et al. looked into the 
differences in gene expression of IGFs and their binding proteins (IGFBPs) present in standard fractures and 
those with non-unions, which were created by cauterisation in rat femur fractures. RNA was extracted from the 
healing callus at the fracture site at various days up to 28 and analysed. They found that in the non-unions the 
expression of both IGF-I and II and IGFBP-6 were present in significantly higher quantities than the controls 
[62]. However they conclude that IGFBP-6 is generally known as an inhibitor of bone formation and therefore 
in opposition to the action of IGFs; more research is needed into the specific actions of the other binding 
proteins to see if they could help in the treatment of fracture healing. IGF-1 was tested in vivo with BMP-9 to 
assess the effect of BMP-9 induced bone formation and was found to enhance BMP-9 induction of osteogenic 
markers such as ALP and osteocalcin and potentiate matrix mineralisation[63]. Interestingly the exposure to the 
Interleukin -1B (IL-1B) had a predominantly negative effect on many growth factors and was found to induce an 
inhibitory migratory response from osteoblasts toward IGF-1, PDGF-BB and VEGF in normal bone[64]. 
In studies which focused on IGF-1 use on fracture healing, the results were positive [63,65,66].  One study 
investigated the effects of MSCs cultured to express IGF-1 to promote their regenerative abilities in regard to 
autocrine and paracrine effects on fracture healing and non-unions in mice. They concluded that the fractures 
with MSC-IGF improved mechanical strength and increased new bone content by speeding up mineralisation of 
bone. Dissected fractures from all groups were subjected to biomechanical testing and uCT analyses which 
measured the change in bone volume from scans taken at the beginning and those at 14 days. They found 
increased strength, elasticity and toughness of the callus in the group with combined MSC and IGF-1 [66].  
Myers et al. looked at the systemic delivery of IGF-1 to enhance MSC fracture healing. This was very similar to 
above [65]. Kumar et al. reiterate the positive effects of IGF on MSCs where they tested MSC mobilisation with 
combinations of different growth factors and their proliferative effect, and IGF-1 was found to have ‘maximum 
proliferative ability’ of MSC in vivo and successful augmentation of bone[67]. See below for a table 
summarising trials involving IGF.  
Type  Study  Trial design Application  Summary  
Pre-Clinical  
 
Koh et al. 
(2011) 
[62] 
In vivo Rodent femur 
non-unions 
 
In non-unions gene expression of IGF-11 and 
IGFBP-6 were significantly higher and IGFBP-
5 lower.  
 
Chen et al. 
(2010) 
[63] 
 
In vitro Embryonic mouse 
limbs 
IGF-2 enhances BMP-9 induced ALP activity 
and mineralisation 
Granero-
molto et al. 
(2011) 
[66] 
In vivo  and 
In vitro  
Rodent tibia 
fractures  
Systemically transplanted MSC expressing IFG 
improved mechanical fracture strength and 
increased new bone content and mineralisation, 
and acted through autocrine and paracrine 
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processes.  
 
Myers et al. 
(2012) 
[65] 
 
In vivo Rodent tibia 
fractures 
In IGF-1 and MSC recipients there were 
increased soft and new bone tissue volumes, 
increased toughness and force compared to 
untreated or MSC alone treated mice.  
 
Kumar et 
al. (2012) 
[67] 
In vivo and 
In vitro  
Mouse tibia 
segmental bone 
defects and MSCs 
cultured from 
their bone marrow 
  
IGF-1 had maximum proliferative ability of 
MSCs when testing the cells in vitro compared 
to several factors. Also when used in vivo for 
mouse tibia fractures IGF-1 use indicated a 
significant augmentation of bone growth and 
stem cell mobilisation.  
 
Summary and characteristics for trials involving Insulin-like Growth Factor: Table 4 
 
4.5 Transforming Growth Factor- Beta (TGF-B) and Platelet Rich Plasma (PRP) 
TGF-B is involved in the proliferation of undifferentiated MSCs, osteoblast recruitment and also 
angiogenesis.[17] It is released by platelets when the haematomas forms and as it accumulates in bone matrix it 
may act as a coupling agent between formation and resorption of bone. There has been some conflicting 
research regarding its effects on bone, as it has been shown by a few studies to exert an inhibitory effect on 
osteogenic cells, while most have found it increases proliferation of these cells. Puleo et al. suggest that it 
depends on the maturation of the TGF-B cells involved at the time[22]. Although Platelet Rich Plasma (PRP) is 
not a cell source itself, it can be used as a source for growth factors to be added to and it can easily be isolated 
from fresh blood.  Autologous PRP can be used in bone regeneration as it has a high concentration of platelets 
and therefore high levels of growth factors (such as TGF-B1, PDGF, VEGF and IGF) which enhance cell 
proliferation, differentiation and also are involved in chemotaxis[3].  
A recent study conducted by Souza et al. in 2012 was about the effect of growth factors TGF-B and PDGF in 
ostectomy gap created in canines. They used PRP containing these growth factors to fill in the gaps created in 
the radius of 21 dogs.  PRP is a small volume of plasma with a high concentration of platelets, and therefore also 
a higher concentration of growth factors that are released by platelets and other proteins [68]. The dogs were 
divided randomly into a control group (who had standard treatment of external fixation alone) or the 
experimental group (who had the fixation as well as PRP to fill the 2.00mm gap created). The results found a 
significant difference in the ‘median radiographic healing score’ and the ratios of healed ostectomies between 
the experimental and the control group at 60 days post operatively (proportion of osteotomies 4/5 healed : 1/5 
healed) and concluded of the successful potential use of PRP in the future. De Gorter et al. also demonstrated 
the co-stimulation of TGF-B with another growth factor, in this case BMPs and found they further increased 
expression of osteoblast-specific genes and ALP activity compared to BMPs alone[69] and in an experiment of 
TGF-B1 and demineralised bone matrix in local application of osteotomies in dogs, increased collagen and 
proteolytic ability was found[70]. 
In order to maximise the effects of PRP, the delivery of it along with growth factors and stem cells has also been 
looked at in recent years, and ‘chitosans’ have been trialled to provide a more vascularised scaffold in bone 
healing; the results look positive as chitosan-PRP incorporated into a bone scaffold highly induced MSC 
differentiation[71]. Similarly PRP has been combined with calcium phosphate cement in different ratios to 
assess its properties. It was found that osteoregeneration, PDGF and other growth factor release and ALP 
activity were all increased in the higher concentrations of PRP (10 and 15 wt%) with the cement, and had a 
significantly better affect than other groups in vitro. In general PRP-CPC was found to be a stable scaffold and 
after immersion in simulated body fluid for 32 days PRP was retained in the cement matrix[72]. In a study of 
minimally invasive intervention (MII) of delayed or non-union fractures 24 patients underwent treatment, with 
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some have MII with iliac crest bone marrow aspirate and blood (containing MSCs and PRP) injected into the 
fracture site. No complications occurred in either group and the median time to union was 3 months for the 
control, and 1.5 months for the experimental group. However, they do explain that both results were 
significantly faster than expected from similar fractures[73].  
However, the use of PRP in skeletal defect has been shown to have no effect on bone healing by Peerbooms et 
al. At one week postoperatively from tibial osteotomies the bone density was significantly lower in the PRP 
group than the control, and this was demonstrated again at 12 weeks, although at 6 weeks there was no 
significant difference[74]. Additionally Leukocyte-PRP was evaluated in autografts of bone defects produced in 
rabbits and bone matrix was found to be significantly less in the defects treated with L-PRP compared to just an 
autograft. It was thought to have interfered with signalling of TGF-B1 and other pathways in maintenance of 
stem cells[75]. PRP was also tested on human synovium-derived MSCs and was seen to have an overall 
negative effect on cell differentiation[76].  
The main challenge presenting with TGF-B1 use is due to a  short half-life,  but it has been found that when 
combined with a novel vector  in a particular composite for a scaffold it greatly accelerated bone healing in 
segmental defects and seemed to maintain its’ bioactivity[77]. See below for tables summarising the trials 
discussed involving TGF-B and PRP. 
Type Study  Trial 
Design   
Application  Summary  
Pre-Clinical  
 
Souza et 
al. (2012) 
[68] 
 
In vivo  Canine Radial 
ostectomy  
 
PRP (containing TGF-B and PDGF) group 
radiographic healing score increased significantly from 
0-60 days, and proportion of healed ostectomies was 
much higher than the control 
De Gorter 
et al. 
(2011)[69] 
Ex vivo Mouse 
pluripotent 
MSCs  
Co-stimulation of BMPs and TGF-B increased 
expression of osteoblasts, ALP activity and 
mineralisation compared with BMPs alone. 
Servin-
trujillo et 
al. (2011) 
[70] 
In vivo Canine tibia, 
open 
osteotomy  
Improvement and restoration of bone in graft with 
TGF-B1 and early formation of bone callus and bone 
regeneration compared to controls. There was also 
increased collagen and proteolytic activity but no 
changes in ALP and clinical parameters. 
Pan et al. 
(2014) 
[77] 
 
Ex vivo and 
In vivo 
Rabbit derived 
MSCs and  
rabbit long 
bone defects 
Ex vivo the group with MSCs and TGF-B1 had 
significantly higher type I collagen, osteocalcin, 
osteopontin and ALP markers compared to other 
groups with MSCs alone. This group had accelerated 
bone regeneration when applied to rabbit bone defects 
in vivo. Conclusions were based on X-rays, histology 
and biomechanical exams.  
Summary and characteristics for trials involving Transforming Growth Factor- Beta: Table 5 
Type  Study  Trial Design   Application  Summary  
Pre-
Clinical  
 
Souza et 
al. (2012) 
[68] 
In vivo  Canine 
Radial 
ostectomy  
 
PRP (containing TGF-B and PDGF) group radiographic 
healing score increased significantly from 0-60 days, 
and proportion of healed ostectomies was much higher 
than the control 
Ko et al. 
(2013) 
[72] 
In vivo and 
In vitro 
Rabbit 
Femurs 
 
Growth factor release and ALP had significantly better 
effect on 10 and 15 wt% (higher PRP conc) than on 
other groups when mixed with calcium phosphate bone 
cement (CPC). PRP was still retained in cement matrix 
after 32 days immersion 
In vivo osteoregeneration was increased in the PRP-
additive group, with this group showing earlier 
breakdown of bulk dense implants compared to CPC-
only group.  
Peerbooms In vivo Human Bone density was significantly lower in the PRP group 
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et al. 
(2012)[74] 
 
skeletal 
defects  
 
compared to control at 1 and 12 weeks in wedge 
fracture.  Overall patients did not benefit from PRP 
addition in this procedure. 
Giovanini 
et al. 
(2013) 
[75] 
In vivo Rabbit skull  
defects  
L-PRP treated defects had significantly less bone matrix 
than control. Results suggested that L-PRP induces a 
cross-reaction between TGF-B1 and other factors, 
impairing the osteoconductive properties of the 
autograft.  
Lee et al. 
(2014) 
[76] 
Ex vivo Human 
synovium 
derived 
MSCs 
PRP on these cells had an overall negative effect and 
does not induce stem cell differentiation. 
Clinical  Calori et 
al. (2013) 
[57] 
In vivo Human bone 
non-unions 
RhBMP-7 vs PRP: clinical and radiological union in 
87% of rhBMP-7 compared to 68% in PRP, and a lower 
clinical and radiographical healing time for the BMP-7 
group (3.5 vs 4 months, and 8 vs 9 months), however 
this study does demonstrate that there was some success 
in using PRP.   
Summary and characteristics for trials involving Platelet Rich Plasma: Table 6 
4.6 Platelet Derived Growth Factor (PDGF) 
PDGF is a signalling molecule which plays a role as a ‘mitogen’ to stimulate mitosis and increases the number 
of bone producing cells and along with other growth factors plays a role in angiogenesis[78]. Caplan et al. wrote 
a review of the effects observed about PDGF with MSCs on bone regeneration and they conclude that in bone 
repair PDGF takes on the role of mobilising pericytes associated with vessel formation and the release of 
activated MSCs, providing stronger healing and bone or callus formation[79]. PDGF is released from platelets 
and can induce the differentiation of MSCs into many different cell types including osteoblasts and fibroblasts. 
It has been shown in preclinical studies that recombinant PDGF-BB enhances bone repair, but the subjects for 
this study had compromised healing such as diabetes and osteoporosis[80]. Tan et al. found that platelet derived 
factors expanded MSCs ex vivo and influenced their response in vivo, as their increase correlated with boosted 
response of MSCs and were much higher in patients who had PRP injected into the iliac crest [81]. See below 
for a summary of trials discussed here. 
Type  Study  Design  Application  Summary  
Pre-Clinical  
 
Souza et al. 
(2012) 
[68] 
In vivo Canine Radial 
ostectomy  
 
PRP (containing TGF-B and PDGF) group 
radiographic healing score increased 
significantly from 0-60 days, and proportion 
of healed ostectomies was much higher than 
the control 
 
Clinical  
 
Tan et al. 
(2015) 
[81] 
In vivo Human bone 
marrow in 
fracture patients 
Direct positive correlation between changes 
in bone marrow MSCs and changes in 
serum PDGF, so they seem to influence 
MSC response in fracture patients. 
 
Summary and characteristics for trials involving Platelet Derived Growth Factor: Table 7 
4.7 Fibroblast Growth Factor (FGF) 
In this family of growth factors FGF-1 and FGF-2 (basic FGF or b-FGF) have been studied the most, and have 
been identified in the early stages of fracture healing with an important regulatory role in bone repair, including 
angiogenesis [22].  In vivo bFGF has been found to help maintain the osteogenic qualities of bone marrow 
MSCs[32]. It was found that DJ-1 (new angiogenic factor secreted by MSCs) promotes angiogenesis by 
activating the FGF-1 signalling and enhanced bone regeneration in a rodent model of fracture repair[82].  
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However in a study by Biver et al. they found a treatment-duration dependant inhibitory effect of FGF-2 on 
mineralisation in bone, regardless of the initial increase in cell proliferation seen and it was found to inhibit the 
up-regulation of BMPs as FGF-2 completely blocked the increase of BMP2 and BMP-4[83]. 
See below for a summary of trials involving FGF  
Type  Study  Design Application  Summary  
Pre-Clinical  
 
Kim et al. 
(2012) 
[82] 
In vivo and 
In vitro 
Rodent fracture DJ-1 was shown to enhance bone 
regeneration and stimulate blood vessels 
and new bones through activation of FGF-1  
 
Biver et al. 
(2012) 
[83] 
Ex vivo Human 
Mesenchymal 
Stem cells 
FGF2 inhibited MSCs differentiation and 
upregulation of BMPs. 
Summary and characteristics for trials involving Fibroblast Growth Factor: Table 8 
 
 
5. Limitations  
There are several limitations that apply to this review. Firstly due to accessibility issues with relevant papers and 
inability to fully analyse all valid database search papers with their reference lists we may have missed some 
relevant material and this increases the effect of selection bias. Similarly there may have been important 
information published in languages not included in our search so this could influence my overall conclusions 
drawn. Therefore we may have missed some negative results in terms of MSC and growth factor use in fractures 
and non-unions. However we tried to keep my inclusion criteria broad in not limiting the publication year, of the 
type of trials looked at, as well as hand searching for related topics to broaden my review from database 
searches and we tried to be as thorough as possible.  
Another limitation lies with the variety of papers and results we have included, in terms of my quantitative data, 
which doesn’t allow for accurate comparison amongst the studies found and only loose conclusions formed for 
each growth factor. Also my search results yielded many more papers regarding MSCs or BMPs but less so with 
the other growth factors, which tend to have only been reviewed in the last few years. Therefore our review does 
focus predominantly on the use of stem cells and bone morphogenetic proteins over other factors. There were 
many more pre-clinical trials found than clinical trials as well so it is hard to compare or draw conclusions for 
the outcomes seen in pre-clinical studies with potential effects if similar trials were conducted on human 
participants.  
6. Conclusion 
In conclusion, it seems that there are many positive findings related to the use of mesenchymal stem cells and 
various growth factors in fracture healing and the treatment of non-union. MSC use in alternative grafts seem to 
be successful and although not many trials exist, the use of alternative sourced MSCs other than bone marrow 
and the delivery via a systemic application provide novel ways for broadening the potential benefits of MSC in 
fracture repair. Alternative MSCs such as adipose cells may overcome previous drawbacks of bone marrow 
MSCs such as lack of vascularisation in bone repair and the addition of other factors to MSCs was also 
successful in enhancing their effects, particularly BMPs and VEGF. 
Recombinant BMP-2 and BMP-7 have been thoroughly analysed and the majority of studies have found them to 
be significantly beneficial in non-unions or delayed fractures and in accelerating healing clinically. But recent 
studies have also highlighted the potential use of BMP1-3 and BMP-9 in bone repair and the novel carrier 
device OSTEOGROW with BMP-6. The ‘diamond concept’ draws together the synergistic effects of growth 
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factors, scaffolds and MSCs and has so far proved to be successful. Further clinical studies are needed to 
confirm the definitive benefit in the treatment of non-unions. However, the results so far are very positive.  
VEGF has been demonstrated to be beneficial for angiogenesis and has an enhanced effect when used in 
conjunction with other factors. IGF has had mixed reviews on its action in bone repair but so far results in 
fracture healing are positive and especially useful when expressed by MSCs. TGF-B1 and PRP have been 
shown to be beneficial in fracture healing but there are diverse results regarding the benefit of PRP. FGF has 
been shown to be involved in vital pathways for bone regeneration but there are only a few studies on this 
growth factor and more are needed pre-clinically. Overall, the study of these growth factors is still in the early 
stages, with more pre-clinical research available than clinical. Much more research is needed on each of these 
before testing the potential applications in a clinical trial or for therapeutic applications. However, so far the 
results of these studies seem very promising for the future of bone regeneration and the potential use of growth 
factors and mesenchymal stem cells.    
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